RCM
REGN icon

Raleigh Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Raleigh Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Sell
52
-15
-22% -$10.2K 0.01% 311
2026
Q1 		$51.8K Buy
67
+3
+5% +$2.3K 0.02% 276
2025
Q4 		$49.4K Buy
+64
New +$43.5K 0.02% 281
2025
Q1 		– Sell
-37
Closed -$26.4K – 932
2024
Q4 		$26.4K Sell
37
-10
-21% -$8.39K 0.01% 409
2024
Q3 		$49.4K Buy
47
+2
+4% +$2.23K 0.02% 318
2024
Q2 		$47.3K Buy
45
+7
+18% +$6.79K 0.02% 305
2024
Q1 		$36.6K Buy
38
+19
+100% +$18.1K 0.02% 340
2023
Q4 		$16.7K Buy
19
+11
+138% +$9.06K 0.01% 477
2023
Q3 		$6.58K Hold
8
– – ﹤0.01% 633
2023
Q2 		$5.75K Hold
8
– – ﹤0.01% 615
2023
Q1 		$6.57K Buy
+8
New +$6.03K ﹤0.01% 578
2022
Q1 		– Sell
-6
Closed -$4K – 664
2021
Q4 		$4K Buy
+6
New +$3.69K ﹤0.01% 251

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Raleigh Capital Management's REGN Position: Q2 2026 in Review

Raleigh Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 22% in Q2 2026, selling an estimated $10.2K and leaving 52 shares worth $32.5K. The position accounts for 0.01% of the portfolio, ranked #311.

Raleigh Capital Management first reported a position in REGN in Q4 2021 and has held it in 12 quarters since. The position peaked at $51.8K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Raleigh Capital Management held 52 shares of Regeneron Pharmaceuticals worth $32.5K as of Q2 2026.
  • Raleigh Capital Management sold 15 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $10.2K.
  • Regeneron Pharmaceuticals made up 0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #311 holding.
  • Raleigh Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Raleigh Capital Management's Regeneron Pharmaceuticals position peaked at $51.8K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.